H. Lundbeck Resultados de beneficios anteriores
Pasado controles de criterios 4/6
H. Lundbeck's earnings have been declining at an average annual rate of -10%, while the Pharmaceuticals industry saw earnings declining at 1.7% annually. Revenues have been growing at an average rate of 1.9% per year. H. Lundbeck's return on equity is 10.4%, and it has net margins of 11.5%.
Información clave
-10.0%
Tasa de crecimiento de los beneficios
-10.0%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 14.1% |
| Tasa de crecimiento de los ingresos | 1.9% |
| Rentabilidad financiera | 10.4% |
| Margen neto | 11.5% |
| Próxima actualización de resultados | 15 May 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero H. Lundbeck. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Dec 23 | 19,912 | 2,290 | 8,706 | 3,457 |
| 30 Sep 23 | 19,614 | 2,467 | 8,426 | 3,386 |
| 30 Jun 23 | 19,381 | 2,479 | 8,248 | 3,476 |
| 31 Mar 23 | 18,918 | 2,384 | 8,082 | 3,617 |
| 31 Dec 22 | 18,246 | 1,916 | 7,689 | 3,754 |
| 30 Sep 22 | 17,619 | 1,603 | 7,398 | 3,846 |
| 30 Jun 22 | 16,913 | 1,236 | 7,127 | 3,947 |
| 31 Mar 22 | 16,398 | 1,109 | 6,768 | 3,884 |
| 31 Dec 21 | 16,299 | 1,318 | 6,625 | 3,820 |
| 30 Sep 21 | 16,521 | 1,873 | 6,698 | 3,711 |
| 30 Jun 21 | 16,971 | 1,965 | 6,680 | 3,655 |
| 31 Mar 21 | 17,381 | 2,110 | 6,720 | 2,999 |
| 31 Dec 20 | 17,672 | 1,581 | 6,912 | 3,753 |
| 30 Sep 20 | 17,818 | 904 | 6,812 | 3,760 |
| 30 Jun 20 | 17,490 | 1,242 | 6,744 | 3,538 |
| 31 Mar 20 | 17,366 | 1,507 | 6,672 | 4,039 |
| 31 Dec 19 | 17,036 | 2,313 | 6,413 | 3,116 |
| 30 Sep 19 | 16,811 | 3,091 | 6,212 | 3,214 |
| 30 Jun 19 | 17,309 | 3,395 | 6,143 | 3,302 |
| 31 Mar 19 | 17,766 | 3,606 | 6,061 | 3,313 |
| 31 Dec 18 | 18,117 | 3,907 | 6,039 | 3,277 |
| 30 Sep 18 | 18,313 | 3,806 | 6,120 | 3,069 |
| 30 Jun 18 | 18,028 | 3,627 | 6,174 | 2,903 |
| 31 Mar 18 | 17,608 | 3,236 | 6,298 | 2,765 |
| 31 Dec 17 | 17,234 | 2,624 | 6,482 | 2,705 |
| 30 Sep 17 | 17,007 | 2,544 | 6,428 | 2,769 |
| 30 Jun 17 | 16,607 | 1,988 | 6,462 | 2,839 |
| 31 Mar 17 | 16,075 | 1,612 | 6,424 | 2,887 |
| 31 Dec 16 | 15,634 | 1,211 | 6,293 | 2,967 |
| 30 Sep 16 | 15,202 | 290 | 6,475 | -1,979 |
| 30 Jun 16 | 14,923 | -1,289 | 7,320 | 3,196 |
| 31 Mar 16 | 14,801 | -5,427 | 7,573 | 3,095 |
| 31 Dec 15 | 14,594 | -5,694 | 7,762 | 3,097 |
| 30 Sep 15 | 14,108 | -5,879 | 7,814 | 8,003 |
| 30 Jun 15 | 13,625 | -4,615 | 6,928 | 2,666 |
| 31 Mar 15 | 13,444 | -565 | 6,581 | 2,790 |
| 31 Dec 14 | 13,468 | -153 | 6,298 | 2,689 |
| 30 Sep 14 | 13,808 | 503 | 6,208 | 2,670 |
| 30 Jun 14 | 14,181 | 765 | 6,147 | 2,782 |
| 31 Mar 14 | 14,269 | 119 | 6,814 | 2,807 |
| 31 Dec 13 | 15,258 | 855 | 6,749 | 2,834 |
| 30 Sep 13 | 15,516 | 1,036 | 6,692 | 2,905 |
| 30 Jun 13 | 15,574 | 1,195 | 6,564 | 2,918 |
Ingresos de calidad: 0ABR has high quality earnings.
Margen de beneficios creciente: 0ABR's current net profit margins (11.5%) are higher than last year (10.5%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 0ABR's earnings have declined by 10% per year over the past 5 years.
Acelerando crecimiento: 0ABR's earnings growth over the past year (19.5%) exceeds its 5-year average (-10% per year).
Beneficios vs. Industria: 0ABR earnings growth over the past year (19.5%) exceeded the Pharmaceuticals industry 3.8%.
Rentabilidad financiera
Alta ROE: 0ABR's Return on Equity (10.4%) is considered low.